These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 8416177

  • 1. The use of desferrioximine in dialysis-associated aluminium disease.
    Ackrill P, Day JP.
    Contrib Nephrol; 1993; 102():125-34. PubMed ID: 8416177
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. The efficacy of various treatment modalities on aluminium associated bone disease.
    Ihle BU, Buchanan MR, Stevens B, Becker GJ, Kincaid-Smith P.
    Proc Eur Dial Transplant Assoc; 1983; 19():195-202. PubMed ID: 6348735
    [Abstract] [Full Text] [Related]

  • 5. Role of desferrioxamine in the treatment of dialysis encephalopathy.
    Ackrill P, Ralston AJ, Day JP.
    Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
    [No Abstract] [Full Text] [Related]

  • 6. Aluminum-associated bone disease: considerations on the pathogenesis and the effects of deferoxamine treatment.
    Kurokawa K, Marumo F, Ogura Y, Ono T, Suzuki M.
    J UOEH; 1987 Mar 20; 9 Suppl():133-9. PubMed ID: 3602744
    [No Abstract] [Full Text] [Related]

  • 7. Diagnosis and treatment of aluminium overload in end-stage renal failure patients.
    Nephrol Dial Transplant; 1993 Mar 20; 8 Suppl 1():1-4. PubMed ID: 8389013
    [No Abstract] [Full Text] [Related]

  • 8. Aluminium in renal disease: current knowledge and future developments.
    Starkey BJ.
    Ann Clin Biochem; 1987 Jul 20; 24 ( Pt 4)():337-44. PubMed ID: 3310831
    [No Abstract] [Full Text] [Related]

  • 9. Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Consensus conference. Paris, France, 27 June 1992.
    Nephrol Dial Transplant; 1993 Jul 20; 8 Suppl 1():1-54. PubMed ID: 8389014
    [No Abstract] [Full Text] [Related]

  • 10. Reversal of aluminium dialysis encephalopathy after desferrioxamine treatment.
    Arze RS, Parkinson IS, Cartlidge NE, Britton P, Ward MK.
    Lancet; 1981 Nov 14; 2(8255):1116. PubMed ID: 6118567
    [No Abstract] [Full Text] [Related]

  • 11. Deferoxamine (DFO): the effectiveness for noninvasive diagnosis of aluminum-related bone disease, and for treatment of the disease.
    Marumo F, Umetani N, Sato N, Takahashi Y.
    J UOEH; 1987 Mar 20; 9 Suppl():140-52. PubMed ID: 3602745
    [No Abstract] [Full Text] [Related]

  • 12. Therapy of aluminium overload (II).
    Ackrill P, Day JP.
    Contrib Nephrol; 1984 Mar 20; 38():78-80. PubMed ID: 6713902
    [No Abstract] [Full Text] [Related]

  • 13. [Aluminum and iron deposition in dialysis patients].
    Kurihara S, Marumo F.
    Nihon Rinsho; 1992 Jan 20; 50 Suppl():905-10. PubMed ID: 1578787
    [No Abstract] [Full Text] [Related]

  • 14. [Indications for desferrioxamine in patients with chronic renal insufficiency treated by dialysis].
    Simon P.
    Nephrologie; 1986 Jan 20; 7(5):177-80. PubMed ID: 3822038
    [No Abstract] [Full Text] [Related]

  • 15. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
    Lillevang ST, Pedersen FB.
    Nephrol Dial Transplant; 1989 Jan 20; 4(7):676. PubMed ID: 2510071
    [No Abstract] [Full Text] [Related]

  • 16. Persisting aluminium-related bone disease after cadaveric renal transplantation.
    Nicholas JC, Dawes PT, Davies SJ, Freemont AJ.
    Nephrol Dial Transplant; 1999 Jan 20; 14(1):202-4. PubMed ID: 10052510
    [No Abstract] [Full Text] [Related]

  • 17. Low aluminium water, desferrioxamine, and dialysis encephalopathy.
    Milne FJ, Sharf B, Bell PD, Meyers AM.
    Lancet; 1982 Aug 28; 2(8296):502. PubMed ID: 6125670
    [No Abstract] [Full Text] [Related]

  • 18. [Successful treatment of progressive dialysis encephalopathy. Case report].
    Weiland P, Köhler M, Glatzel E.
    Z Urol Nephrol; 1985 Jul 28; 78(7):387-93. PubMed ID: 4050157
    [Abstract] [Full Text] [Related]

  • 19. Rapid conversion from aluminium bone disease to hyperparathyroid bone disease by desferrioxamine.
    Terao N, Suzuki M, Homma S, Asano Y, Hosoda S, Furuse M.
    Nihon Jinzo Gakkai Shi; 1988 Sep 28; 30(9):1129-33. PubMed ID: 3216555
    [No Abstract] [Full Text] [Related]

  • 20. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM, Corwin HL, Wilson RS, Mayor GH, Tanner CM.
    Arch Intern Med; 1986 Oct 28; 146(10):2063-4. PubMed ID: 3767553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.